Use of FKBP-L polypeptides and nucleic acids for the treatment of obesity

Patent metadata

Field	Value
Publication number	US-11376308-B2
Application number	US-201716343266-A
Country	US
Kind code	B2
Filing date	Oct 18, 2017
Priority date	Oct 19, 2016
Publication date	Jul 5, 2022
Grant date	Jul 5, 2022

Abstract

The inventors have determined that increasing the expression level or activity of FKBP-L polypeptide in a subject, which can be provided by expression of nucleic acids encoding FKBP-L or by providing FKBP-L polypeptides to a subject is advantageous for use in the treatment of obesity and obesity-related disorders. In particular increased expression or activity of FKBP-L polypeptide in a subject may be used to treat excessive weight gain (which can be characterised as obesity), glucose intolerance, diabetes and metabolic syndrome, which are closely linked to obesity and insulin resistance. FKBP-L can also be used as a biomarker for obesity and obesity-related disorders.

First claim

The invention claimed is:

1. A method of treating obesity comprising the step of administering to a subject in need thereof, a FK506-binding protein like (FKBP-L) nucleic acid or polypeptide, wherein the FKBP-L nucleic acid or polypeptide is selected from the group consisting of:
(a) a FKBP-L polypeptide encoded by the nucleotide sequence of SEQ ID NO: 30;
(b) a FKBP-L polypeptide that consists of the amino acid sequence NH2-TIRQQPRDPPTETLELEVSPDPAS-OH (SEQ ID NO: 40);
(c) a FKBP-L polypeptide that consists of the amino acid sequence NH2-QIRQQPRDPPTETLELEVSPDPAS-OH (SEQ ID NO: 10);
(d) a nucleic acid capable of being expressed to provide a FKBP-L polypeptide that consists of the amino acid sequence NH2-IRQQPRDPPTETLELEVSPDPAS-OH (SEQ ID NO:40); and
(e) a nucleic acid capable of being expressed to provide a FKBP-L polypeptide that consists of the amino acid sequence NH2-QIRQQPRDPPTETLELEVSPDPAS-OH (SEQ ID NO: 10).

2. The method of claim 1 , wherein the nucleic acid or polypeptide sequence further comprises a delivery peptide.

3. The method of claim 2 , wherein the delivery peptide is an RALA peptide.

Assignees

• Univ Belfast
• Royal College Surgeons Ireland

Inventors

• Robson Tracy
• Grieve David
• Short Amy
• Kissenpfennig Adrien
• Migaud Marie
• Bennett Rachel
• Yakkundi Anita
• Mccarthy Helen

Classifications

• A61K38/17

  from animals; from humans {(enzyme inhibitors A61K38/005)} · CPC title

• A61K38/1709 Primary

  from mammals · CPC title

• A61P3/04

  Anorexiants; Antiobesity agents · CPC title

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title